Breast Cancer in South Asia
Death rates for Breast Cancer across 6 countries in South Asia.
| # | Country | Rate |
|---|
Breast cancer is the most commonly diagnosed cancer worldwide and the leading cause of cancer death in women, claiming approximately 685,000 lives annually. Incidence is highest in high-income countries (due to screening detection, reproductive patterns, and lifestyle factors), but mortality is disproportionately concentrated in low- and middle-income countries where late-stage diagnosis and limited treatment access prevail. Hormonal factors — early menarche, late menopause, nulliparity, and exogenous hormone use — increase risk, as do obesity, alcohol consumption, physical inactivity, and genetic predisposition (BRCA1/BRCA2 mutations). Molecular subtypes (luminal A/B, HER2-positive, triple-negative) have distinct prognoses and treatment implications. Five-year survival exceeds 90% for early-stage disease in well-resourced settings but falls below 40% in countries lacking diagnostic and treatment capacity. The global disparity in breast cancer outcomes represents one of the starkest inequities in cancer care. South Asia — home to nearly two billion people — contends with a dual burden of persistent infectious diseases alongside rapidly rising non-communicable conditions linked to urbanisation, dietary shifts, and air pollution. In South Asia, breast cancer mortality falls near the global average, reflecting the region's ongoing epidemiological transition from communicable to non-communicable disease dominance.
Mammographic screening detects breast cancer at earlier, more treatable stages and reduces mortality by approximately 20% in screened populations. Risk reduction includes maintaining a healthy weight, limiting alcohol intake, and regular physical activity. Chemoprevention with tamoxifen or aromatase inhibitors is an option for high-risk women. Surgical treatment, radiation therapy, endocrine therapy, and targeted therapies (trastuzumab for HER2-positive disease) have improved survival dramatically. The WHO Global Breast Cancer Initiative aims to reduce global breast cancer mortality by 2.5% per year through improved early detection and treatment access.
The mortality estimates presented on this page are derived from the Global Burden of Disease (GBD) study, produced by the Institute for Health Metrics and Evaluation (IHME). The GBD synthesizes data from vital registration systems, verbal autopsies, cancer registries, and surveillance networks across more than 200 countries and territories. Death rates are expressed per 100,000 population and are age-standardized, which adjusts for differences in age structure between populations so that comparisons across countries and over time reflect genuine differences in mortality risk rather than demographic composition.
The dataset typically covers the period from 1990 to 2023, although availability varies by country and cause. When interpreting the figures for breast cancer in South Asia, note that higher age-standardized rates indicate a greater mortality burden independent of whether a country's population is older or younger. Trends over time reveal whether public health interventions, economic development, and health system improvements have reduced or increased the toll of this condition in the region.
Cancer mortality data combine information from population-based cancer registries, vital registration systems, and statistical modeling where direct data are sparse. Incidence-to-mortality ratios and survival estimates help distinguish regions where high death rates stem from high incidence versus those where limited access to early detection and treatment drives poor outcomes. For breast cancer across South Asia, comparing mortality rates alongside screening coverage and treatment availability provides crucial context for understanding regional disparities.